Welcome to our dedicated page for Plus Therapeutics news (Ticker: PSTV), a resource for investors and traders seeking the latest updates and insights on Plus Therapeutics stock.
Plus Therapeutics, Inc. (NASDAQ: PSTV) generates a steady flow of news as a clinical-stage pharmaceutical and healthcare company focused on targeted radiotherapeutics and precision diagnostics for central nervous system (CNS) cancers. Headquartered in Houston, Texas, the company regularly reports on its clinical trial progress, regulatory interactions, capital markets activity, and expansion of its CNSide Diagnostics subsidiary.
News about Plus Therapeutics often highlights developments related to REYOBIQ™ (rhenium Re186 obisbemeda), its lead investigational radiotherapy for recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. Updates include clinical data presentations at major oncology meetings, safety and efficacy findings from the ReSPECT-GBM and ReSPECT-LM trials, and discussions with the U.S. Food and Drug Administration (FDA) on pivotal trial design and potential accelerated approval pathways.
Another key news theme is the company’s CNSide Diagnostics, LLC subsidiary and the CNSide® CSF Assay Platform. Press releases describe new state laboratory licenses, national coverage agreements with major payors, and real-world utilization metrics for the CNSide cerebrospinal fluid Tumor Cell Enumeration test used in managing leptomeningeal metastases.
Investors following PSTV can also expect announcements on financing and listing matters, such as public offerings of common stock and warrants, purchase agreements with institutional investors, and updates on Nasdaq listing compliance related to minimum bid price and equity standards. Corporate governance items, including proxy statements and stockholder meeting results, appear in both news and SEC filings.
This news page aggregates these updates so readers can track Plus Therapeutics’ clinical milestones, diagnostic platform expansion, regulatory communications, and capital markets events in one place. For those researching PSTV, it provides context on how the company is advancing its CNS cancer programs and managing its public company obligations over time.
Plus Therapeutics (Nasdaq: PSTV) granted inducement equity awards on March 26, 2026 to two new employees under its 2015 New Employee Incentive Plan.
The awards total 300,000 stock options (10-year term, $0.243 exercise price) and 300,000 RSUs. Options vest over four years; RSUs vest over three years.
Plus Therapeutics (NASDAQ: PSTV) announced a 1-for-25 reverse stock split effective 12:01 a.m. ET on April 2, 2026, to increase its per-share trading price and comply with Nasdaq's $1.00 minimum bid requirement.
Outstanding shares will be reduced from ~171,550,698 to ~6,862,027, a new CUSIP 72941H806 will be assigned, fractional shares will be paid in cash, and equity awards and warrants will be adjusted.
Plus Therapeutics (Nasdaq: PSTV) appointed diagnostics veteran Ron Andrews to its Board of Directors on March 26, 2026. Andrews brings over 35 years in diagnostics, experience leading Abbott, Roche, Thermo Fisher units and public startups, and has been involved in >$600M capitalization and ~$15B in exits.
He will support scaling CNSide, a cerebrospinal-fluid diagnostic for leptomeningeal metastases, and advise strategy, fundraising and commercialization efforts for the company’s diagnostics business.
Plus Therapeutics (Nasdaq: PSTV) will present a health economics analysis at ISPOR 2026 showing the CNSide CSF assay could cut leptomeningeal metastases (LM) healthcare costs by ~40% (range 33%–47%).
Key figures: median inpatient admissions ~$20,000 (IQR $10,000–$30,000) and LM costs may exceed $100,000 per month; findings support U.S. commercialization efforts.
Plus Therapeutics (Nasdaq: PSTV) reported full-year 2025 results and provided 2026 milestones for REYOBIQ clinical programs and CNSide commercial rollout. Key highlights include a $15 million upsized public offering, $13.1 million cash and investments at year-end, CPT Category III reimbursement for convection-enhanced delivery, and expanded CNSide lab licensing to 49 states.
The company expects REYOBIQ ReSPECT-LM data in Q3 2026, ReSPECT-GBM data in Q4 2026, increased 2026 R&D and G&A spend, and targets >150 million payer coverage and Medicare pathway for CNSide.
Plus Therapeutics (NASDAQ: PSTV) announced the AMA CPT Editorial Panel approved a new Category III CPT code X566T to track convection-enhanced delivery (CED) used with REYOBIQ for recurrent glioblastoma and pediatric brain cancer. The code will be published July 1, 2026 and effective for reporting January 1, 2027.
The company said the code enables standardized utilization tracking, may inform future coverage and reimbursement, and supports REYOBIQ commercialization while Plus advances clinical enrollment milestones in 2026.
Plus Therapeutics (NASDAQ: PSTV) provided a business update on REYOBIQ clinical progress and U.S. commercialization of CNSide, announcing an upsized $15 million offering to fund 2026 priorities and extend cash runway through 2027. Key 2026 milestones include REYOBIQ dose optimization and data in Q3 2026, ReSPECT-GBM data and FDA end-of-phase alignment in Q4 2026, commercial manufacturing scale-up, and ReSPECT-PBC Phase 1 enrollment. CNSide targets include coverage for 150 million US lives, Medicare/Medicaid coverage, >1,250 tests/year, and launch of additional CSF tumor characterization tests. A conference call and webcast are scheduled for January 22, 2026 at 9:00 a.m. ET.
Plus Therapeutics (NASDAQ: PSTV) will provide a business update on Thursday, January 22, 2026 before the market opens and host a conference call and webcast at 9:00 AM ET. Management will discuss recent developments and provide additional details.
Webcast and dial-in information: webcast URL available, participant dial-in 1-888-349-0106 (please dial in 15 minutes early). A replay will be available on the company website for 90 days after the live call.
Plus Therapeutics (NASDAQ: PSTV) priced an upsized underwritten public offering of 39,473,684 units at $0.38 per unit, producing expected gross proceeds of approximately $15 million before underwriting discounts, commissions and expenses. Each unit includes one share of common stock and one warrant exercisable immediately at $0.38 per share and expiring five years from issuance.
The underwriter has a 30‑day option to purchase up to an additional 5,921,052 shares and/or warrants to cover over‑allotments. Proceeds are intended for working capital and general corporate purposes. The offering is expected to close on January 15, 2026, subject to customary closing conditions; Lake Street Capital Markets is sole underwriter. Registration statements were declared effective January 13, 2026.
Plus Therapeutics (NASDAQ:PSTV) completed a Type B meeting with the FDA on Jan 8, 2026 to discuss a potential pivotal trial strategy for REYOBIQ in leptomeningeal metastases (LM).
The FDA indicated accelerated approval may be appropriate for LM but said circulating tumor cells (CTCs) lack sufficient data to serve as an intermediate clinical endpoint. The agency recommended a primary endpoint with established clinical benefit (for example, overall survival), discussed randomized controlled trial designs including an intrathecal chemotherapeutic comparator, and said multiple histologies may be reasonable in one trial. Plus plans to incorporate FDA feedback into its dose‑optimization trial, seek protocol alignment later in 2026, and accelerate manufacturing scale‑up to target pivotal trial readiness in late 2026.